2018 American Transplant Congress
Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Liver/Kidney Transplantation
Virginia Commonwealth University, Richmond, VA.
Introduction: There is no data on the risks and benefits of induction immunosuppression in simultaneous liver/kidney transplant (SLKT) patients.Methods: We analyzed all SLKT performed between…2018 American Transplant Congress
Cancer Incidence after Kidney Transplantation in Saudi Arabia, Comparing Different Induction Agents
Kidney and Pancreas Transplantation, King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
Cancer incidence varies among different induction agents and different population. We aim to compare the incidence of cancer post kidney transplantation among different induction agents…2018 American Transplant Congress
Optimal Protocol for ABO Incompatible Kidney Transplantations: Analysis of 400 Cases in a Single Center Experience
Asan Medical Center, Seoul, Korea.
This study describes the single center experience and long-term results of ABOincompatible kidney transplantation (ABO i KT).Four hundred patientswhoreceived an ABOi KT in the period…2018 American Transplant Congress
Single-Dose Basiliximab Induction in Liver Transplant Recipients with Delayed CNI Initiation
Liver transplant recipients (LTR) with peri-operative renal injury benefit from a delayed CNI protocol using basiliximab (IL2RA) induction to reduce early CNI exposure. Existing literature…2018 American Transplant Congress
Induction Agents and Post-Transplant Malignancies in Kidney Transplants: An Examination of Outcomes at a Large Volume Center over 20 Years
Division of Transplant Surgery, University of Wisconsin, Madison, WI.
Introduction: Induction agents have a profound effect on the immune milieu at the time of kidney transplantation. However, evaluation of their long-term effects on graft…2018 American Transplant Congress
Optimal Anti-Thymocyte Globulin Dose for Induction Immunosuppression in Kidney Transplantation
Organ Transplant Program, Swedish Medical Center, Seattle, WA.
Anti-thymocyte globulin (ATG) is used as induction immunosuppression in kidney transplantation to prevent allograft rejection. ATG causes dose-dependent lymphocyte depletion, yet optimal dose is unknown.…2018 American Transplant Congress
Hepatitis C Recurrence after Liver Transplant: A Comparison of Antibody Induction versus No Antibody Induction
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Hepatitis C virus (HCV) recurrence after orthotopic liver transplant (OLT) is universal and exhibits accelerated progression to cirrhosis. Progression can be mitigated by new…2018 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
Department of Surgery, Duke University Medical Center, Durham, NC.
IntroductionThe field of porcine islet xenotransplantation has made significant progress in non-human primate studies in recent years. However, one major barrier preventing clinical translation of…2018 American Transplant Congress
T Cell Exhaustion in Kidney Transplant Patients
Background: T cell exhaustion is a dysfunctional state that arises during chronic infection and cancer in response to persistence of high antigenic load. Whether chronic…2018 American Transplant Congress
Risk of Bacteremia According to Transplant Induction Immunosuppression Regimen
University of Wisconsin School of Medicine and Public Health, Madison.
Background: Transplant immune suppression is designed to suppress the adaptive immune response and ensure graft survival, but may have unintended effects on innate immunity. Few…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 31
- Next Page »